公开(公告)号：EP1518926A1

公开(公告)日：2005-03-30

申请号：EP03761839.4

申请日：2003-06-30

申请人： Okada, Hidechika ,  Okada, Noriko

发明人： Okada, Hidechika ,  Okada, Noriko

IPC分类号： C12N15/06 ,  C12N5/20 ,  C07K16/28 ,  C12P21/08

CPC分类号： C07K16/28 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/56 ,  Y10S530/809

摘要： A human IgM monoclonal antibody responding to HIV-infected cells too, which is characterized by lysing activated human lymphocytes, etc. under the mediation by a homologous human complement, is obtained. Using the thus obtained monoclonal antibody, it is intended to provide an immune reaction controlling remedy, etc. containing the human IgM monoclonal antibody which responds specifically to activated lymphocytes and induces cell lysis under the mediation by a homologous complement. Using the human IgM monoclonal antibody responding to activated human lymphocytes, it is also intended to provide an HTV remedy, etc. characterized by lysing and eliminating activated lymphocytes to thereby treat transplantation rejection and autoimmune diseases caused by an over-response of T lymphocytes as well as HIV infection

公开(公告)号：EP1518926A4

公开(公告)日：2005-11-23

申请号：EP03761839

申请日：2003-06-30

申请人： OKADA HIDECHIKA ,  OKADA NORIKO

发明人： OKADA HIDECHIKA ,  OKADA NORIKO

IPC分类号： C07K16/28 ,  C12N5/20 ,  C12N15/06 ,  C12P21/08

CPC分类号： C07K16/28 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/56 ,  Y10S530/809

摘要： A human IgM monoclonal antibody responding to HIV-infected cells too, which is characterized by lysing activated human lymphocytes, etc. under the mediation by a homologous human complement, is obtained. Using the thus obtained monoclonal antibody, it is intended to provide an immune reaction controlling remedy, etc. containing the human IgM monoclonal antibody which responds specifically to activated lymphocytes and induces cell lysis under the mediation by a homologous complement. Using the human IgM monoclonal antibody responding to activated human lymphocytes, it is also intended to provide an HIV remedy, etc. characterized by lysing and eliminating activated lymphocytes to thereby treat transplantation rejection and autoimmune diseases caused by an over-response of T lymphocytes as well as HIV infection

摘要翻译： 还获得了对HIV感染细胞有反应的人IgM单克隆抗体，其特征在于通过同源人补体介导裂解活化的人淋巴细胞等。 使用由此获得的单克隆抗体，旨在提供含有人IgM单克隆抗体的免疫反应控制疗法等，所述人IgM单克隆抗体对活化的淋巴细胞特异应答并在同源补体的介导下诱导细胞裂解。 使用对活化的人淋巴细胞有反应的人IgM单克隆抗体，也可以提供一种HIV补救剂等，其特征在于裂解和消除活化的淋巴细胞，从而治疗由T淋巴细胞过度反应引起的移植排斥和自身免疫性疾病 作为HIV感染

公开(公告)号：EP0672421B1

公开(公告)日：2002-03-20

申请号：EP94927840.2

申请日：1994-10-04

申请人： Kurashiki Boseki Kabushiki Kaisha ,  Okada, Hidechika

发明人： OHSHIMA, Kunihiro ,  KAWAMURA, Seiko ,  YAMAMOTO, Ryohei ,  NISHINO, Toyokazu ,  OKADA, Hidechika ,  BARANYI, Lajos

IPC分类号： A61K38/17

CPC分类号： C07K14/72 ,  A61K38/00 ,  A61K39/00

摘要： An endothelin activity inhibitor containing a peptide containing such a part of the amino acid sequence of a human endothelin receptor as will correspond to the region wherein at least 80 % of the amino acid residues are complementary to each other when the amino acid sequence estimated on the basis of the cDNA of a human endothelin receptor is compared with the one estimated on the basis of the cDNA of a human endothelin precursor, an analog thereof, and a conjugate thereof with a macromolecule or a macromolecular peptide. The inhibitor can be provided at a low cost and has a relatively low melecular weight, so that it can be used not only as a reagent for detecting endothelins but also as a remedy for various diseases wherein endothelins participate.

公开(公告)号：EP0351313A2

公开(公告)日：1990-01-17

申请号：EP89401996.7

申请日：1989-07-11

申请人： Okada, Hidechika ,  Mitsubishi Chemical Corporation

发明人： Okada, Hidechika ,  Okada, Noriko ,  Nagami, Yoichi ,  Takahashi, Kazuhiro ,  Takizawa, Hisao ,  Kondo, Jun

IPC分类号： C07K15/00

CPC分类号： C07K14/4703 ,  A61K38/00 ,  C07K14/8107 ,  Y10S530/827

摘要： The present invention provides a glycoprotein derived from human cell membrane, which has a molecular weight of 20 to 25 Kd as estimated by SDS polyacrylamide gel electrophoresis, and contains N-glycoside type carbohydrate chain and phosphatidylinositol, and possesses an inhibitory activity to complement.mediated cell membrane damage. The present invention further provides a gene coding for the glycoprotein, and a method for the production of the glycoprotein and the gene therefor.

摘要翻译： 本发明提供衍生自人细胞膜的糖蛋白，其通过SDS聚丙烯酰胺凝胶电泳估计的分子量为20〜25Kd，并含有N-糖苷型碳水化合物链和磷脂酰肌醇，并具有补体的抑制活性。 细胞膜损伤。 本发明还提供了编码糖蛋白的基因，以及糖蛋白的制造方法及其基因。

公开(公告)号：EP1681568A1

公开(公告)日：2006-07-19

申请号：EP04792372.7

申请日：2004-10-14

申请人： Okada, Hidechika ,  Okada, Noriko

发明人： Okada, Hidechika ,  Okada, Noriko

IPC分类号： G01N33/531 ,  C07K7/06 ,  C07K7/08 ,  C07K14/00

CPC分类号： G01N33/6854 ,  C07K14/001 ,  C07K2318/20

摘要： It is intended to design and synthesize a peptide complementary to the target site of an antigen protein, confirm the ability thereof to bind to the target site and thus provide an artificial peptide for detecting the antigen protein. Namely, an artificial antibody peptide wherein the specific binding of a complementary peptide, which has been constructed by using, for example, a designing program MIMETIC for automatically designing a complementary peptide corresponding to the amino acid sequence of a peptide at the target site, to the target site is confirmed to give an artificial antibody peptide.

摘要翻译： 旨在设计和合成与抗原蛋白的靶位点互补的肽，确认其与靶位点结合的能力，从而提供用于检测抗原蛋白质的人工肽。 也就是说，其中通过使用例如用于自动设计对应于目标部位的肽的氨基酸序列的互补肽的设计程序MIMETIC构建的互补肽的特异性结合的人工抗体肽， 确认目标部位产生人工抗体肽。

公开(公告)号：EP0351313A3

公开(公告)日：1991-09-11

申请号：EP89401996.7

申请日：1989-07-11

申请人： Okada, Hidechika ,  Mitsubishi Chemical Corporation

发明人： Okada, Hidechika ,  Okada, Noriko ,  Nagami, Yoichi ,  Takahashi, Kazuhiro ,  Takizawa, Hisao ,  Kondo, Jun

IPC分类号： C07K15/00

CPC分类号： C07K14/4703 ,  A61K38/00 ,  C07K14/8107 ,  Y10S530/827

摘要： The present invention provides a glycoprotein derived from human cell membrane, which has a molecular weight of 20 to 25 Kd as estimated by SDS polyacrylamide gel electrophoresis, and contains N-glycoside type carbohydrate chain and phosphatidylinositol, and possesses an inhibitory activity to complement.mediated cell membrane damage. The present invention further provides a gene coding for the glycoprotein, and a method for the production of the glycoprotein and the gene therefor.